May 25, 2017

Redefining a "Meaningful" Alzheimer's Drug - Dr. Howard Fillit


Redefining a "Meaningful" Alzheimer's Drug - Dr. Howard Fillit

About This Episode

Dr. Howard Fillit joined George Vradenburg for this month’s Alzheimer’s Talks to discuss a new report he co-authored, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease”. The report proposes a change in how we define a clinically meaningful drug and therefore the framework for FDA approvals of a possible Alzheimer’s treatment.

Dr. Fillit is the Founding Executive Director and Chief Science Officer at the Alzheimer’s Drug Discovery Foundation and a founding member of our ResearchersAgainstAlzheimer’s network.


Key Highlights

It’s time to change the way we measure a drug’s effectiveness.

Standards were set based on decades-old knowledge, and drugs were deemed effective if there were improvements in both cognition and function, co-primary endpoints.

Several advances mean standards need to change.    

New developments in biomarkers, such as PET scans, mean that scientists can now determine, with certainty, if someone has Alzheimer’s disease or not. This was not the case 40 years ago. Now, when people take part in clinical trials, we know they have Alzheimer’s disease and the results of the trials are much more relevant.

We have to set realistic expectations.

If we don’t create realistic expectations for the clinical meaningfulness of a drug, we may reduce investment in research. The voice of the patient and caregiver is also crucial to determine what is clinically meaningful.

Other drugs, for conditions such as heart disease, have a single primary endpoint. For Alzheimer’s disease, composite cognition might be the only clinical primary endpoint needed in certain drug trials as there is a fairly linear relationship between loss of cognition and loss of function. A modernization of standards for Alzheimer’s drugs, to make them meaningful and approvable, is necessary.

Prevention is a priority.

Improvements in public health have reduced risk factors. For example, more exercise, better diets, and better management of hypertension and diabetes have been shown to reduce Alzheimer’s risk.

The Alzheimer’s Drug Discovery Foundation has a website called Cognitive Vitality that evaluates the efficacy, safety, and evidence of possible preventions, including supplements and diets.


BrainStorm Feed


Mary Lou Falcone - Breaking through the Silence and Stigma of Lewy Body Dementia

Lewy Body Dementia is the second most progressive form of dementia after Alzheimer's and impacts an estimated one mil


Leigh Callahan, PhD – Breaking through the Silence and Stigma of Alzheimer’s (part 2)

In this episode of BrainStorm host Meryl Comer continues her care partner conversation with Leigh Callahan, a respected epidemiologist and research


Leigh Callahan, PhD - Breaking through the Silence and Stigma of Alzheimer’s (part 1)

The care partner is the keeper of the secrets and their perspective is essential to break through the silence and stigma of Alzheimer’s disease.